Hybrid Bio (www.hybrid-bio.com) is an early-stage biotech created by a group of scientists and industry executives to develop a novel cell therapy approach in oncology. Our technology, which originated in the University of Pennsylvania, is a revolutionary novel type of autologous combinational cell therapy enhancing the efficacy of therapeutic antibodies in solid and liquid tumors. It is based on newly discovered Hybrid Neutrophils possessing unique composite features of cytotoxic and antigen-presenting (APCs) effector cells, both killing the tumor and generating tumor-specific systemic immune response in the patient.